Brent R Logan

List of Publications by Year
in descending order

163 papers	8,891 citations	53794 45 h-index	46799 89 g-index
167 all docs	167 docs citations	167 times ranked	9243 citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. New England Journal of Medicine, 2012, 367, 1487-1496.	27.0	762
2	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood, 2014, 123, 3664-3671.	1.4	730
3	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009. New England Journal of Medicine, 2014, 371, 434-446.	27.0	594
4	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Clinical Oncology, 2017, 35, 1154-1161.	1.6	495
5	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. Journal of Clinical Oncology, 2020, 38, 1273-1283.	1.6	281
6	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncology, The, 2011, 12, 1195-1203.	10.7	263
7	Analyzing survival curves at a fixed point in time. Statistics in Medicine, 2007, 26, 4505-4519.	1.6	256
8	Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2015, 21, 454-459.	2.0	256
9	Immune reconstitution and survival of 100 SCID patients post–hematopoietic cell transplant: a PIDTC natural history study. Blood, 2017, 130, 2718-2727.	1.4	212
10	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	4.6	200
11	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood, 2014, 124, 1372-1377.	1.4	178
12	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood, 2016, 128, 2561-2567.	1.4	174
13	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1479-1487.	2.0	173
14	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood, 2018, 132, 1737-1749.	1.4	128
15	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biology of Blood and Marrow Transplantation, 2016, 22, 359-370.	2.0	127
16	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood, 2021, 137, 420-428.	1.4	119
17	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood, 2014, 123, 3655-3663.	1.4	112
18	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. JAMA Oncology, 2016, 2, 1583.	7.1	110

#	Article	IF	Citations
19	An evaluation of thresholding techniques in fMRI analysis. NeuroImage, 2004, 22, 95-108.	4.2	109
20	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. Journal of Clinical Immunology, 2013, 33, 1156-1164.	3.8	100
21	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biology of Blood and Marrow Transplantation, 2018, 24, 1049-1056.	2.0	98
22	Nonparametric survival analysis using Bayesian Additive Regression Trees (BART). Statistics in Medicine, 2016, 35, 2741-2753.	1.6	95
23	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood, 2014, 124, 3221-3227.	1.4	92
24	National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2021, 39, 1971-1982.	1.6	90
25	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1183-1189.	2.0	89
26	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood, 2020, 135, 2094-2105.	1.4	87
27	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	1.6	79
28	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. Biology of Blood and Marrow Transplantation, 2014, 20, 858-864.	2.0	78
29	Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biology of Blood and Marrow Transplantation, 2014, 20, 1530-1536.	2.0	78
30	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. Journal of Clinical Oncology, 2014, 32, 2365-2372.	1.6	77
31	Observational Studies: Matching or Regression?. Biology of Blood and Marrow Transplantation, 2016, 22, 557-563.	2.0	76
32	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT. Blood, 2017, 129, 162-170.	1.4	75
33	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. Journal of Clinical Oncology, 2021, 39, 3328-3339.	1.6	72
34	Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era. Biology of Blood and Marrow Transplantation, 2015, 21, 142-150.	2.0	66
35	Primary Immune Deficiency Treatment Consortium (PIDTC) report. Journal of Allergy and Clinical Immunology, 2014, 133, 335-347.e11.	2.9	65
36	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). Journal of Allergy and Clinical Immunology, 2019, 143, 405-407.	2.9	64

#	Article	IF	Citations
37	Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients. Clinical Cancer Research, 2016, 22, 69-78.	7.0	63
38	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Blood, 2015, 126, LBA-8-LBA-8.	1.4	59
39	Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	2.5	58
40	Comparing Treatments in the Presence of Crossing Survival Curves: An Application to Bone Marrow Transplantation. Biometrics, 2008, 64, 733-740.	1.4	57
41	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 2020, 11, 239.	4.8	57
42	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood, 2020, 135, 97-107.	1.4	56
43	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	3.5	53
44	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. Journal of Clinical Oncology, 2015, 33, 364-369.	1.6	51
45	Deep Reinforcement Learning for Dynamic Treatment Regimes on Medical Registry Data. , 2017, 2017, 380-385.		49
46	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biology of Blood and Marrow Transplantation, 2018, 24, 1274-1280.	2.0	46
47	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biology of Blood and Marrow Transplantation, 2015, 21, 1308-1314.	2.0	45
48	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2016, 22, 1440-1448.	2.0	44
49	Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. American Journal of Neuroradiology, 2018, 39, 1008-1016.	2.4	43
50	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Journal of Clinical Immunology, 2019, 39, 653-667.	3.8	41
51	The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. Blood, 2019, 133, 754-762.	1.4	40
52	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. JAMA Oncology, 2020, 6, 486.	7.1	39
53	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Advances, 2020, 4, 467-476.	5.2	39
54	Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data. Biology of Blood and Marrow Transplantation, 2006, 12, 107-112.	2.0	38

#	ARTICLE	IF	CITATIONS
55	Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression. Blood, 2016, 128, 2068-2082.	1.4	38
56	ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 746-754.	2.0	37
57	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood, 2018, 131, 2967-2977.	1.4	37
58	Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSFâ€"mobilized stem cell transplantation. Blood Advances, 2019, 3, 2250-2263.	5.2	37
59	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. Journal of Clinical Immunology, 2021, 41, 38-50.	3.8	36
60	Multiple Test Procedures for Identifying the Minimum Effective and Maximum Safe Doses of a Drug. Journal of the American Statistical Association, 2002, 97, 293-301.	3.1	35
61	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2015, 21, 55-59.	2.0	34
62	A phase II/III randomized, multicenter trial of prednisone/sirolimus *versus* prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-*versus*-host disease: BMT CTN 0801. Haematologica, 2018, 103, 1915-1924.	3.5	34
63	An evaluation of spatial thresholding techniques in fMRI analysis. Human Brain Mapping, 2008, 29, 1379-1389.	3.6	33
64	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplantation, 2020, 55, 906-917.	2.4	33
65	Marginal Models for Clustered Time-to-Event Data with Competing Risks Using Pseudovalues. Biometrics, 2011, 67, 1-7.	1.4	32
66	Decision making and uncertainty quantification for individualized treatments using Bayesian Additive Regression Trees. Statistical Methods in Medical Research, 2019, 28, 1079-1093.	1.5	32
67	Moving Toward a Consensus DSC-MRI Protocol: Validation of a Lowâ€"Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. American Journal of Neuroradiology, 2019, 40, 626-633.	2.4	30
68	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biology of Blood and Marrow Transplantation, 2020, 26, 333-342.	2.0	30
69	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biology of Blood and Marrow Transplantation, 2018, 24, 2040-2046.	2.0	29
70	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer, 2018, 18, 593.	2.6	28
71	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 798-804.	2.0	28
72	Race and Ethnicity Influences Collection of Granulocyte Colonyâ€"Stimulating Factorâ€"Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2015, 21, 165-171.	2.0	26

#	Article	IF	Citations
73	Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. Biology of Blood and Marrow Transplantation, 2016, 22, 1108-1116.	2.0	26
74	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. Transplantation and Cellular Therapy, 2021, 27, 507-516.	1.2	26
75	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood, 2022, 140, 685-705.	1.4	26
76	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. Biology of Blood and Marrow Transplantation, 2014, 20, 1566-1572.	2.0	24
77	Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. Blood, 2011, 118, 1-1.	1.4	24
78	Use of biological assignment in hematopoietic stem cell transplantation clinical trials. Clinical Trials, 2008, 5, 607-616.	1.6	21
79	European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. Biology of Blood and Marrow Transplantation, 2016, 22, 514-519.	2.0	21
80	Pairwise multiple comparison adjustment in survival analysis. Statistics in Medicine, 2005, 24, 2509-2523.	1.6	20
81	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 2256-2263.	2.0	20
82	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. Blood, 2012, 120, 739-739.	1.4	19
83	A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with *FLT3-*ITD+ AML.. Journal of Clinical Oncology, 2018, 36, TPS7075-TPS7075.	1.6	17
84	Analyzing center specific outcomes in hematopoietic cell transplantation. Lifetime Data Analysis, 2008, 14, 389-404.	0.9	16
85	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 688-695.	2.0	16
86	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. JAMA Oncology, 2020, 6, e192974.	7.1	15
87	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biology of Blood and Marrow Transplantation, 2016, 22, 520-527.	2.0	14
88	Nonparametric competing risks analysis using Bayesian Additive Regression Trees. Statistical Methods in Medical Research, 2020, 29, 57-77.	1.5	14
89	Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning. JCO Clinical Cancer Informatics, 2021, 5, 494-507.	2.1	14
90	Accurate Critical Constants for the One-Sided Approximate Likelihood Ratio Test of a Normal Mean Vector When the Covariance Matrix Is Estimated. Biometrics, 2002, 58, 650-656.	1.4	13

#	Article	IF	Citations
91	Superiority Inferences on Individual Endpoints Following Noninferiority Testing in Clinical Trials. Biometrical Journal, 2008, 50, 693-703.	1.0	13
92	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biology of Blood and Marrow Transplantation, 2019, 25, 1325-1330.	2.0	13
93	Learning the Dynamic Treatment Regimes from Medical Registry Data through Deep Q-network. Scientific Reports, 2019, 9, 1495.	3.3	13
94	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica, 2019, 104, 844-854.	3.5	13
95	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. JCO Precision Oncology, 2021, 5, 265-274.	3.0	13
96	The use of group sequential designs withâ€‰common competing risks tests. Statistics in Medicine, 2013, 32, 899-913.	1.6	12
97	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biology of Blood and Marrow Transplantation, 2015, 21, 1830-1838.	2.0	12
98	On Oâ€™Brienâ€™s OLS and GLS tests for multiple endpoints. Lecture Notes-monograph Series / Institute of Mathematical Statistics, 2004, , 76-88.	1.0	12
99	Review of Multistate Models in Hematopoietic Cell Transplantation Studies. Biology of Blood and Marrow Transplantation, 2013, 19, S84-S87.	2.0	11
100	Quality of Life of Patients with Wiskott Aldrich Syndrome and X-Linked Thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation. Journal of Clinical Immunology, 2019, 39, 786-794.	3.8	11
101	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation, 2019, 25, 699-711.	2.0	11
102	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. Blood, 2015, 126, 193-193.	1.4	11
103	The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases. Blood, 2012, 120, 737-737.	1.4	11
104	Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). Biology of Blood and Marrow Transplantation, 2017, 23, 161-164.	2.0	10
105	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. Bone Marrow Transplantation, 2019, 54, 1780-1788.	2.4	10
106	Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients. Biology of Blood and Marrow Transplantation, 2020, 26, 745-757.	2.0	10
107	Comorbidity Index (CI) in Autologous Hematopoietic Cell Transplantation (HCT) for Malignant Diseases: Validation of the HCT-CI. Blood, 2012, 120, 814-814.	1.4	10
108	Optimal two-stage randomized phase II clinical trials. Clinical Trials, 2005, 2, 5-12.	1.6	8

#	Article	IF	Citations
109	Statistical Methods for Time-Dependent Variables in Hematopoietic Cell Transplantation Studies. Transplantation and Cellular Therapy, 2021, 27, 125-132.	1.2	8
110	Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Blood, 2014, 124, 206-206.	1.4	8
111	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
112	Regarding â€œRecipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survivalâ€• Biology of Blood and Marrow Transplantation, 2019, 25, e268-e269.	2.0	7
113	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biology of Blood and Marrow Transplantation, 2019, 25, 955-964.	2.0	7
114	Impact of autologous blood transfusion after bone marrow harvest on unrelated donorâ€™s health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.	2.4	7
115	Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. Biology of Blood and Marrow Transplantation, 2020, 26, e142-e144.	2.0	7
116	5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood. Blood, 2015, 126, 270-270.	1.4	7
117	A unified approach to sample size and power determination for testing parameters in generalized linear and timeâ€toâ€event regression models. Statistics in Medicine, 2021, 40, 1121-1132.	1.6	6
118	Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 650-657.	1.2	6
119	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2014, 124, 422-422.	1.4	6
120	Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. Journal of Clinical Oncology, 2022, 40, 7571-7571.	1.6	6
121	A cone order monotone test for the one-sided multivariate testing problem. Statistics and Probability Letters, 2003, 63, 315-323.	0.7	5
122	Group sequential tests for long-term survival comparisons. Lifetime Data Analysis, 2015, 21, 218-240.	0.9	5
123	A cureâ€rate model for Qâ€learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients. Biometrical Journal, 2019, 61, 442-453.	1.0	5
124	Larger Numbers of Donor NaÃ¯ve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201. Blood, 2011, 118, 1004-1004.	1.4	5
125	A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study. Blood, 2015, 126, 619-619.	1.4	5
126	Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.. Journal of Clinical Oncology, 2020, 38, e23551-e23551.	1.6	5

#	Article	IF	Citations
127	Pseudo-value approach for conditional quantile residual lifetime analysis for clustered survival and competing risks data with applications to bone marrow transplant data. Annals of Applied Statistics, 2016, 10, 618-637.	1.1	4
128	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a <scp>BMT CTN</scp> 0102 correlative study. British Journal of Haematology, 2017, 178, 816-819.	2.5	4
129	A Group Sequential Test for Treatment Effect Based on the Fineâ€"Gray Model. Biometrics, 2018, 74, 1006-1013.	1.4	4
130	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biology of Blood and Marrow Transplantation, 2020, 26, 1210-1217.	2.0	4
131	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation.. Blood, 2005, 106, 443-443.	1.4	4
132	Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays â€" Comparison with Electrophoretic Responses in Multiple Myeloma (MM). Blood, 2011, 118, 2877-2877.	1.4	4
133	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2012, 120, 733-733.	1.4	4
134	The Likelihood of Hematopoietic Stem Cell Transplantation (HCT) in the United States: Implications for Umbilical Cord Blood Storage.. Blood, 2005, 106, 1330-1330.	1.4	4
135	Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic. Blood, 2021, 138, 2846-2846.	1.4	4
136	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. Transplantation and Cellular Therapy, 2022, 28, 406.e1-406.e6.	1.2	4
137	Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. Leukemia and Lymphoma, 2022, 63, 2507-2510.	1.3	4
138	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. Open Forum Infectious Diseases, 2021, 8, ofab441.	0.9	3
139	Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 34-35.	1.4	3
140	BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). Blood, 2008, 112, 55-55.	1.4	3
141	Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR). Blood, 2013, 122, 1687-1687.	1.4	3
142	Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicuar Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701). Blood, 2014, 124, 682-682.	1.4	3
143	Psychosocial services for primary immunodeficiency disorder families during hematopoietic cell transplantation: A descriptive study. Palliative and Supportive Care, 2019, 17, 409-414.	1.0	2
144	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Transplantation and Cellular Therapy, 2021, 27, 503.e1-503.e8.	1.2	2

#	Article	IF	Citations
145	Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. Transplantation and Cellular Therapy, 2021, 27, 352.e1-352.e5.	1.2	2
146	BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). Blood, 2019, 134, 1955-1955.	1.4	2
147	CFU-GM Assay Can Be Predictive of Umbilical Cord Blood Engraftment.. Blood, 2006, 108, 5212-5212.	1.4	2
148	Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?.. Blood, 2009, 114, 649-649.	1.4	2
149	Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. Blood, 2010, 116, 3486-3486.	1.4	2
150	Excellent Outcomes After Umbilical Cord Blood Transplantation Using a Centralized Cord Blood Registry. Stem Cells Translational Medicine, 2018, 7, S1-S1.	3.3	1
151	Testing for center effects on survival and competing risks outcomes using pseudo-value regression. Lifetime Data Analysis, 2019, 25, 206-228.	0.9	1
152	Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point. Lifetime Data Analysis, 2020, 26, 603-623.	0.9	1
153	COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum. Transplantation and Cellular Therapy, 2021, 27, 533-539.	1.2	1
154	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. Blood, 2021, 138, 1772-1772.	1.4	1
155	Phenyl N-Tert-Butylnitrone (PBN) Protects Syngeneic Marrow Transplant Recipients from the Lethal Cytokine Syndrome Occurring after Agonistic CD40 Antibody Administration.. Blood, 2004, 104, 2128-2128.	1.4	0
156	Peripheral Blood Stem Cell (PBSC) Donors Experience Higher Levels of Pain and Toxicities Early On, While Bone Marrow (BM) Donors Experience Slower Recovery and More Late Pain: A Prospective Study of the National Marrow Donor Program (NMDP).. Blood, 2010, 116, 1107-1107.	1.4	0
157	Survival Of AML Patients Relapsing After Allogeneic Stem Cell Transplantation: A Center For International Blood and Marrow Transplant Research Study. Blood, 2013, 122, 2072-2072.	1.4	0
158	Baseline Symptoms, Female Sex, and Younger Age Are Correlated with Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year after Related Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe). Blood, 2014, 124, 3847-3847.	1.4	0
159	Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801). Blood, 2019, 134, 2005-2005.	1.4	0
160	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2020, 136, 7-8.	1.4	0
161	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2020, 136, 33-34.	1.4	0
162	BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). Blood, 2020, 136, 40-41.	1.4	0

#	Article	IF	Citations
163	Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 7-8.	1.4	0